MedTrace Logo

ShotBloker and Helfer Skin Tap Technique During Intramuscular Injection in Children

NCT05563233 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 177

Last updated 2023-11-27

No results posted yet for this study

Summary

To examine the effect of the Helfer skin tap technique and ShotBloker application on pain and fear experienced during intramuscular injection in children aged 6-12 in the pediatric emergency unit. It was planned as a randomized controlled experimental study to determine its effect on fear. The population of the study will be children aged 6-12 years who applied to the Tarsus State Hospital, and Pediatric Emergency Clinic and the sample will be 177 children who will undergo intramuscular intervention and meet the criteria for inclusion in the study. In data collection; Data collection form, Wong-Baker Scale, and Child fear scale will be used. In order to examine the mean scores of pain and fear according to intramuscular administration techniques in children, appropriate tests will be used by making an analysis of conformity to normal distribution.

Conditions

  • Pain, Acute
  • Fear
  • Emergencies
  • Child, Only
  • Injection Fear

Interventions

OTHER

Helfer skin tap technique

Using the Helfer skin tap technique during intramuscular injection to the ventrogluteal region.

DEVICE

Shot Blocker

Shot Blocker will be used during intramuscular injection to be applied to the ventrogluteal region.

Sponsors & Collaborators

  • Tarsus University

    lead OTHER

Principal Investigators

  • Duygu Sönmez Düzkaya · Tarsus University

  • Senem Andı · Tarsus Univesity

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-10
Primary Completion
2023-11-10
Completion
2023-11-10

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05563233 on ClinicalTrials.gov